Disappointment for Advanced NSCLC Patients Expressing EGFR WT

Phase II study findings show only marginal positive effects of third-line treatment with afatinib for advanced non-small-cell lung cancer (NSCLC) in patients with wild-type epidermal growth-factor receptor (EGFR) tumour status.
Published Online: June 24, 2014

Phase II study findings show only marginal positive effects of third-line treatment with afatinib for advanced non-small-cell lung cancer (NSCLC) in patients with wild-type epidermal growth-factor receptor (EGFR) tumour status.

There were no confirmed complete or partial responses, and only a quarter of the cohort achieved disease control, for a median of 19.3 weeks, report the researchers in The Oncologist.

There is currently no standard therapy for this population, the team notes, and while the current findings reveal only limited clinical benefit of afatinib, the fact that there was even marginal benefit “highlights the need to investigate further the opportunities for biomarker-driven therapy in wild-type EGFR patients.”

Keunchil Park, from the Samsung Medical Center in Seoul, Republic of Korea, and co-workers, investigated the efficacy of the irreversible inhibitor of the ErbB receptor family – afatinib – in a group of 38 stage IIIB/IV NSCLC patients aged a median of 58 years who had previously been tested by direct sequencing and found to have wild-type EGFRtumours. All patients had undergone two previous chemotherapy regimens, and all received 40 mg afatinib orally, on a 28-day dosing cycle.

Read the original report here: http://bit.ly/1lnJg1B

Source: News-Medical



Feature
Recommended Articles
New delivery models related to the recent healthcare reform legislation may help drive up utilization, as discussed by Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, in this seventh segment of the Healthcare Reform Stakeholders Summit, Spring 2015 series. They theorize that healthcare convenience and availability may actually lead to a loss in coordination of care.
With a growing understanding of the risk of cardiotoxicity associated with cancer treatment, cardio-oncology has emerged as an important subspecialty, resulting in the establishment of cardio-oncology programs most often based at or in collaboration with comprehensive cancer centers.
During this one-on-one interview, a part of the Oncology Stakeholders Summit, Spring 2015 series, Michael Kolodziej, MD, discusses payer considerations regarding coverage for new cancer treatments such as immuno-oncology therapies.
Metastatic colorectal cancer patients with higher body mass index (BMI) outlived patients with the lowest BMI by an average of 2-and-a-half months, according to new data presented at the European Society for Medical Oncology 17th World Congress on Gastrointestinal Cancer 2015.
The fact that a small percentage of the population accounts for roughly half of healthcare spending in the United States is not new information. Now a new white paper from the Health Care Transformation Task Force has taken a look at what healthcare systems can do to identify these individuals in order to better manage their care and lower spending.